Cargando…
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer and the prognosis of children with relapsed or therapy refractory disease remains a challenge. Treatment with chimeric antigen receptor-modified T cells targeting the CD19 antigen (CART-19 therapy) has been presented as a...
Autores principales: | Fischer, Jeannette, Paret, Claudia, El Malki, Khalifa, Alt, Francesca, Wingerter, Arthur, Neu, Marie A., Kron, Bettina, Russo, Alexandra, Lehmann, Nadine, Roth, Lea, Fehr, Eva-M., Attig, Sebastian, Hohberger, Alexander, Kindler, Thomas, Faber, Jörg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424577/ https://www.ncbi.nlm.nih.gov/pubmed/28441264 http://dx.doi.org/10.1097/CJI.0000000000000169 |
Ejemplares similares
-
Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL
por: Ziegler, Nicole, et al.
Publicado: (2023) -
Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy
por: Paret, Claudia, et al.
Publicado: (2016) -
Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells
por: Lehmann, Nadine, et al.
Publicado: (2020) -
Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020) -
Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1
por: Paret, Claudia, et al.
Publicado: (2021)